Evaluation of renal adverse effects of combination anti-retroviral therapy including tenofovir in HIV-infected patients

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 16, Issue 3, 2013, Pages 405-413

  Tanaka, Hiroyuki ^a,c   Arai, Mariko ^a   Tomoda, Yoshinori ^a   Wada, Tatsuhiko ^b   Yago, Kazuo ^a   Satoh, Mitsutoshi ^c  

^a KITASATO UNIVERSITY HOSPITAL   (Japan)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOHO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; DARUNAVIR; EFAVIRENZ; EMTRICITABINE; FOSAMPRENAVIR; LAMIVUDINE; LOPINAVIR; RALTEGRAVIR; RITONAVIR; TENOFOVIR DISOPROXIL;

ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT OUTCOME;

EID: 84878207459     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j32p5c     Document Type: Article

References (26)

1. Cooper DA. Life and death in the cART era. Lancet 2008; 372(9635): 266-267.
2. Karras A, Lafaurie M, Furco A, Bourgarit A, Droz D, Sereni D, Legendre C, Martinez F, Molina JM. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003; 36:1070-1073.
3. Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 2006; 42: 283-290.
4. Gallant JE, Moore RD. Renal function with use of a tenofovir-containing initial antiretroviral regimen. AIDS 2009; 23:197-205.
5. Horberg M, Tang B, Towner W, Silverberg M, Bersoff-Matcha S, Hurley L, Chang J, Blank J, Quesenberry C Jr, Klein D. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. J Acquir Immune Defic Syndr 2010; 53: 62-69.
6. Nelson MR, Katlama C, Montaner JS, Cooper DA, Gazzard B, Chen SS, Smith S, Bischofberger N, Rooney JF. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 2007; 21: 1273-1281.
7. Nishijima T, Komatsu H, Gatanaga H, Aoki T, Watanabe K, Kinai E, Honda H, Yazaki H, Tsukada K, Honda M, Teruya K, Kikuchi Y, Oka S. Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients. PLos One 2011; 6: e22661.
8. Goicoechea M, Liu S, Best B, Sun S, Jain S, Kemper C, Witt M, Diamond C, Haubrich R, Louie S; California Collaborative Treatment Group 578 Team. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor based therapy. J Infect Dis 2008; 197: 102-108.
9. Rodrigues-Novoa S, Labarga P, Davolio A, Barreiro P, Albalate M, Vispo E, Solea C, Siccardi M, Bonora S, Di Perri G, Soriano V. Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. AIDS 2010; 24: 1064-1066.
10. Kohler JJ, Hosseini SH, Hoying-Brandt A, Green E, Johnson DM, Russ R, Tran D, Raper CM, Santoianni R, Lewis W. Tenofovir renal toxicity targets mitochondria of renal proximal tubules. Lab Invest 2009; 89: 513-519.
11. Ray AS, Cihlar T, Robinson KL, Tong L, Vela JE, Fuller MD, Wieman LM, Eisenberg EJ, Rhodes GR. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother 2006; 50: 3297-3304.
12. Kohler JJ, Hosseini SH, Green E, Abuin A, Ludaway T, Russ R, Santoianni R, Lewis W. Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters. Lab Invest 2011; 91: 852-858.
13. Izzedine H, Holot JS, Villard E, Goyenvalle C, Dominguez S, Ghosn J, Valantin MA, Lechat P, Deray G. Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis 2006; 194: 1481-1491.
14. Kiser JJ, Carten ML, Aquilante CL, Anderson PL, Wolfe P, King TM, Delahunty T, Bushman LR, Fletcher CV. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther 2008; 83: 265-272.
15. Miller DS. Nucleoside phosphonate interactions with multiple organic anion transporters in renal proximal tuble. J Pharmacol Exp Ther 2001; 299: 567-574.
16. Izzedine H, Launaly-Vacher V, Deray G. Renal tubular transporters and antiviral drugs: an update. AIDS 2005; 19: 455-462.
17. Young J, Schafer J, Fux CA, Furrer H, Bernasconi E, Vernazza P, Calmy A, Cavassini M, Weber R, Battegay M, Bucher HC, the Swiss HIV Cohort Study. Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. AIDS 2012; 26: 567-575.
18. Pacanowski J, Poirier JM, Petit I, Meynard JL, Girard PM. Atazanavir urinary stones in an HIV-infected patient. AIDS 2006; 20: 2131.
19. Chan-Tack KM, Truffa MM, Struble K, Birnkrant DB. Atazanavir-associated nephrolithiasis: case from the US Food and Drug Administration's adverse event reporting system. AIDS 2007; 21: 1215-1218.
20. Rockwood N, Mandalia S, Bower M, Gazzard B, Nelson M. Ritonavir-boosted atazanavir exposure is associated with an incrased rate of renal stones compared with efavirenz, titonavir-boosted lopinavir and ritonavir-boosted darunavir. AIDS 2011; 25: 1671-1673.
21. Kassahun K, Mclntosh I, Cui D, Hreniuk D, Merschman S, Lasseter K, Azrolan N, Iwamoto M, Wagner JA, Wenning LA. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos 2007; 35: 1657-1663.
22. Wennig LA, Friedman EJ, Kost JT, Breidinger SA, Stek JE, Lasseter KC, Gottesiener KM, Chen J, Teppler H, Wagner JA, Stone JA, Iwamoto M. Lack of a significant drug interaction between raltegravir and tenofovir. Antimicrob Agents Chemother 2008; 52: 3253-3258.
23. Menezes AM, Torelly J Jr, Real L, Bay M, Poeta J, Sprinz E. Prevalence and risk factors associated to chronic kidney disease in HIV-infected patients on HAART and undetectable viral load in Brazil. PLoS One 2011; 6: e26042.
24. Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, Beniowski M, Gatell J, Phillips AN, Ledergerber B, Lundgren JD; EuroSIDA Study Grop. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 2010; 24: 1667-1678.
25. Yanagisawa N, Ando M, Ajisawa A, Imamura A, Suganuma A, Tsuchiya K, Nitta K. Clinical characteristics of kidney disease in Japanese HIV-infected patients. Nephron Clin Pract 2011; 118: c285-291.
26. Gatanaga H, Tachikawa N, Kikuchi Y, Teruya K, Genka I, Honda M, Tanuma J, Yazaki H, Ueda A, Kimura S, Oka S. Urinary β2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate. AIDS Res Hum Retroviruses 2006; 22: 744-748.